Harding Loevner

Harding Loevner Global Developed Markets Equity

Global Mega-cap

Dec 2024 → Sep 2026

Our archive holds 10 letters from this strategy, behind 6 investment theses and positions in 64 companies. Every quote below is copied verbatim from the letter it came from.

10 letters in 3 years · follow all of Harding Loevner for every strategy.

What it bought and sold

  • ExitedBooking HoldingsSep 2026
    The portfolio also exited AstraZeneca and Booking Holdings as their investment theses weakened.
  • New positionNeurocrine BiosciencesSep 2026
    Health Care positioning has also evolved, most recently with the purchase of Neurocrine Biosciences.
  • ExitedDeereSep 2026
    Electrical-products manufacturer Atkore received a takeover offer at a 30% premium to its share price, while Deere’s strong stock run lifted the agricultural-equipment maker’s valuation above our analyst’s most optimistic estimate.
  • ExitedAstraZenecaSep 2026
    The portfolio also exited AstraZeneca and Booking Holdings as their investment theses weakened.
  • the portfolio exited Vertex in the second quarter due to concern about whether its efforts to build a second growth platform in kidney disease could ultimately match the success of its cystic fibrosis franchise.
  • ExitedAtkoreSep 2026
    Electrical-products manufacturer Atkore received a takeover offer at a 30% premium to its share price, while Deere’s strong stock run lifted the agricultural-equipment maker’s valuation above our analyst’s most optimistic estimate.
  • AddedLenovoSep 2026
    declining valuations in semiconductor and hardware stocks created an opportunity to add exposure to Hong Kong-listed personal- computer manufacturer Lenovo.

Also held

Its investment theses

Every letter